Development Pipeline
Using aiProtein® technology, we design gain-of-function (GOF) enzymes to overcome the challenges of mRNA therapy, developing “GOF-enhanced mRNA therapeutics.” This approach is expected to be applicable to a wide range of inherited diseases as a new therapeutic modality.
As of June, 2026
| Project | Indication | Partner | Lead Discovery | PreClinical | Clinical | ||
|---|---|---|---|---|---|---|---|
| Ph1 | Ph2 | Ph3 | |||||
| RKD001/003 | Rare Disease（Phenylketonuria） |
|
|||||
| RKD002 | Rare Disease |
|
|||||
| RKD004 | Rare Disease | Undisclosed | |||||
Research Presentation
-
RevolKa Director & CSO Prof. Mitsuo Umetsu (Tohoku-Univ.) and Team Announce New AI-Driven Method toAccelerate Discovery of Highly Functional Antibodies
-
Poster presentation at “Antibody engineering & therapeutics Asia”
-
【Update】We Will Exhibit at “Global Startup EXPO 2025”
-
We Will Exhibit at “PEGS Europe”
-
We Will Exhibit at “Antibody Engineering 2025″
-
We Will Exhibit at “Global Startup EXPO 2025”
-
Presentation movie uploaded at Antibody Engineering & Therapeutics 2023
-
Presenting at Antibody Engineering & Therapeutics
-
Presenting at the AACR ANNUAL MEETING 2023
-
Presenting at CPHI Japan
